Multi-Center Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activatio
Not Applicable
Completed
- Conditions
- ocally advanced or metastatic solid tumors with activating RET alterations (and other evidence of RET activation).
- Registration Number
- JPRN-jRCT2080225226
- Lead Sponsor
- oxo Oncology, Inc.,Wholly owned subsidiary of Eli Lilly and Company / CMIC Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib.
Exclusion Criteria
Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method